Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FDPS | P14324 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.34 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3802703 | 1.00 | DNM1 (0.42) | DNM1LPAR1LPAR3SMPD1GPR84 | |
| SCHEMBL5936869 | 1.00 | DNM1 (0.42) | DNM1LPAR1LPAR3SMPD1GPR84 | |
| SCHEMBL250415 | 0.96 | DNM1 (0.45) | DNM1LPAR1LPAR3SMPD1GPR84 | |
| SCHEMBL2531986 | 0.96 | DNM1 (0.45) | DNM1LPAR1LPAR3SMPD1GPR84 | |
| SCHEMBL11131659 | 0.96 | DNM1 (0.45) | DNM1LPAR1LPAR3SMPD1GPR84 | |
| SCHEMBL3806150 | 0.96 | DNM1 (0.45) | DNM1LPAR1LPAR3SMPD1GPR84 | |
| SCHEMBL4655596 | 0.96 | DNM1 (0.45) | DNM1LPAR1LPAR3SMPD1GPR84 | |
| SCHEMBL724922 | 0.96 | DNM1 (0.45) | DNM1LPAR1LPAR3SMPD1GPR84 | |
| SCHEMBL459228 | 0.96 | DNM1 (0.45) | DNM1LPAR1LPAR3SMPD1GPR84 | |
| SCHEMBL6554402 | 0.96 | DNM1 (0.45) | DNM1LPAR1LPAR3SMPD1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114177182-A | Application of sildenafil citrate/tadalafil/vardenafil in preparation of medicine for treating myopia | 三维医疗科技有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-113398252-A | Eye drop rich in animal and plant active ingredients and preparation method thereof | 李宇宙 | 2021-09-17 | — | — | CN | claimed |
| EP-3032949-B1 | COMPOSITION COMPRISING MICROPARTICLES FOR CLEANING AND PROTECTION OF TECHNICAL MATERIAL | AIMECS GMBH (DE) | 2021-03-03 | — | — | EP | claimed |
| EP-3230795-B1 | EMBOSSING LACQUER AND METHOD FOR EMBOSSING | JOANNEUM RES FORSCHUNGSGMBH (AT) | 2019-06-05 | — | — | EP | claimed |
| EP-3423037-A1 | ORALLY ADMINISTRABLE COMPOSITION | CTT Pharma Inc. (CA) | 2019-01-09 | — | — | EP | claimed |
| US-20170252300-A1 | ORALLY ADMINISTRABLE COMPOSITION | CTT PHARMA INC. (CA) | 2017-09-07 | — | — | US | claimed |
| EP-2834355-A1 | POLYSILICATE-POLYSILICONE ENZYME IMMOBILIZATION MATERIALS | Akermin, Inc. (US) | 2015-02-11 | — | — | EP | claimed |
| WO-2013151757-A1 | POLYSILICATE-POLYSILICONE ENZYME IMMOBILIZATION MATERIALS | AKERMIN, INC. (US) | 2013-10-10 | — | — | WO | claimed |
| US-8173113-B1 | Bioadhesive composition and patch | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-08 | — | — | US | claimed |
| EP-2362809-A2 | PROCESS FOR ACCELERATED CAPTURE OF CARBON DIOXIDE | Akermin, Inc. (US) | 2011-09-07 | — | — | EP | claimed |
| EP-0813421-A1 | LIQUID FORMULATIONS FOR PROTEINIC PHARMACEUTICALS COMPRISING AT LEAST 2 ABSORPTION ENHANCERS | MODI, Pankaj (CA) | 1997-12-29 | — | — | EP | claimed |
| US-5676931-A | DRUG DELIVERY | ABBOTT LABORATORIES (US) | 1997-10-14 | — | — | US | claimed |
| EP-0621775-B1 | PELLETS CONTAINING PEPTIDE DRUGS, THEIR MANUFACTURE AND USE | ALFATEC PHARMA GMBH (DE) | 1997-08-06 | — | — | EP | claimed |
| US-5653987-A | FOR ORAL DELIVERY OF INSULIN | MODI PANKAJ (CA) | 1997-08-05 | — | — | US | claimed |
| WO-1996036352-A1 | LIQUID FORMULATIONS FOR PROTEINIC PHARMACEUTICALS COMPRISING AT LEAST 2 ABSORPTION ENHANCERS | MODI PANKAJ (CA) | 1996-11-21 | — | — | WO | claimed |
| WO-1996035709-A1 | METHOD FOR REFOLDING INSOLUBLE AGGREGATES OF HEPATITIS C VIRUS PROTEASE | SCHERING CORPORATION (US) | 1996-11-14 | — | — | WO | claimed |
| EP-0731688-A1 | AEROSOL DRUG FORMULATIONS FOR USE WITH NON-CFC PROPELLANTS | Abbott Laboratories (US) | 1996-09-18 | — | — | EP | claimed |
| EP-0408370-B1 | Stable tretinoin emulsified cream formulations | BRISTOL MYERS SQUIBB CO (US) | 1995-09-13 | — | — | EP | claimed |
| WO-1995015151-A1 | AEROSOL DRUG FORMULATIONS FOR USE WITH NON-CFC PROPELLANTS | ABBOTT LABORATORIES (US) | 1995-06-08 | — | — | WO | claimed |
| US-5182258-A | Passage into nasolacrimal duct and absorption into circulation | ORBON CORPORATION (US) | 1993-01-26 | — | — | US | claimed |